A suppressor cell that is not suppressing anything useful in scleroderma

Design

Human cohort with flow cytometry and histology, integrated single-cell and spatial transcriptomics, and a bleomycin mouse model

Population

37 patients with systemic sclerosis and 27 controls (blood); 9 and 5 (skin); transcriptomic cohorts of 19 and 20 skin, 7 and 15 lung

Primary outcome

Abundance and interactions of granulocytic MDSCs in systemic sclerosis

Effect

G-MDSCs enriched in blood and skin and correlated with severity; a G-MDSC to ILC2 axis driving fibrosis via IL-13, TGF-beta, arginase 1 and CCL24

Myeloid-derived suppressor cells were named for what they do in tumours — dampen T cell responses — and their role in fibrotic autoimmune disease has been unclear. This study makes a case that in systemic sclerosis the granulocytic subset is not a bystander but part of the fibrotic machinery.

The human data are modest in size but consistent: flow cytometry on blood from 37 patients with systemic sclerosis and 27 controls, and skin biopsies from 9 and 5, found granulocytic MDSCs enriched in both circulation and skin, correlating with disease severity. Monocytic MDSCs did not change. The mechanism comes from integrating single-cell RNA sequencing of skin and lung with spatial transcriptomics of skin, which put granulocytic MDSCs in conversation with type 2 innate lymphoid cells, driving a pro-fibrotic programme through IL-13, TGF-beta, arginase 1 and CCL24. Functional assays confirmed that the MDSCs induce Tgfb1 expression in the ILC2s, and in bleomycin-treated mice, disrupting granulocytic MDSC activity with the Bruton tyrosine kinase inhibitor ibrutinib attenuated fibrosis.

The ibrutinib result is the part that will be over-read, so take it carefully. It is a pharmacological tool used to interrogate a pathway in a mouse model, not a therapeutic proposal — BTK inhibition has broad effects well beyond MDSCs, and the bleomycin model prevents fibrosis far more readily than any drug reverses it in a patient. What the paper earns is a named axis to target and a candidate severity correlate.

• Nothing to prescribe — do not extrapolate to BTK inhibitors in scleroderma.
• Keep annual screening for interstitial lung disease and pulmonary hypertension; that is where outcomes are actually changed.
• Record modified Rodnan skin score consistently so real progression is visible.
• Note the IL-13 arm — it connects this to a cytokine already druggable in other diseases.

Why it matters

It gives scleroderma fibrosis a specific cellular conversation to interrupt, rather than a cytokine to blanket.

Don't overread it

The ibrutinib finding is a mechanistic probe in mice, not evidence for BTK inhibition in patients.

The statistics, in plain English

Thirty-seven patients and 9 skin biopsies is a small human cohort, and 'correlating with disease severity' is reported without a coefficient, so treat it as a direction rather than a measurable relationship. The strength of the paper is convergence rather than sample size: flow cytometry, single-cell sequencing, spatial transcriptomics, functional assays and a mouse model all point the same way, which is harder to produce by chance than any one of them alone. It remains association in humans and causation only in mice.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.